Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is operating in a highly competitive and fragmented segment. It marked almost static top lines for the reported periods and boosted bottom line for FY24. Based on FY24 super earnings, the issue is exorbitantly priced. There is no harm in skipping this risky bet. Read detail review...
Clinitech Laboratory Limited peer comparison with similar listed entities. (As on March 31, 2024)
| Company Name | EPS (Basic) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|
| Clinitech Laboratory Limited | 2.37 | 21.12 | 43.45 | 10.46 | 4.55 | |
| Dr Lalpath Labs | 43.05 | 225.85 | 67.92 | 19.19 | 12.03 | Consolidated |
| Thyrocare Technologies Ltd | 13.42 | 99.65 | 47.56 | 13.17 | 6.41 | Consolidated |
| Krsnaa Diagnostics Limited | 17.90 | 250.79 | 38.42 | 7.02 | 2.74 | Consolidated |
Notes:
Clinitech Laboratory IPO Reviews, analysis and views by popular members. Read Clinitech Laboratory Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP